XOMA has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies.
Investor Relations. We use a portfolio approach to acquire new royalty assets, thereby mitigating single-asset binary exposure, and we operate under a ...
An AST shareholder services representative can be reached at 800-937-5449 or 718-921-8124 between the hours of 8 a.m. and 8 p.m. Eastern Time, Monday through ...
XOMA to Present at Upcoming Investor Conferences in March. February 28, 2024. XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and ...
XOMA Corporation, a biotech royalty aggregator, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific.
Missing: investor relations
[PDF] Corporate Presentation | XOMA
www.xoma.com › wp-content › uploads › 2024/04 › 04-24-Corporat...
Apr 4, 2024 · NOTE: All references to “portfolio” in this presentation are to milestone and/or royalty rights associated with a basket of drug products in.
Missing: relations | Show results with:relations
Feb 28, 2024 · XOMA's presentations can also be accessed by visiting the investor relations section of the Company's website at www.xoma.com. A replay of ...
